Medication info
Yuhan Metformin Extended-Release Tablets 1000 mg (Metformin Hydrochloride)

Yuhan Metformin Extended-Release Tablets 1000 mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
White rectangular extended-release film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202103063 · Approved 2021.04.13 · Insurance code 642105770

Summary

Main use
Treatment of type 2 diabetes mellitus in adults whose blood glucose is inadequately controlled by diet and exercise
Who takes it
Adults
Adult dose
The dose should be determined individually based on efficacy and tolerability, and the recommended maximum daily dose should not be exceeded. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week. A maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg 2 times daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - During treatment initiation and dose adjustment, measure fasting blood glucose to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The treatment goal with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine should be discontinued immediately.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults whose blood glucose is inadequately controlled by diet and exercise

  • Type 2 diabetes not adequately controlled
View approved original text

This medication is used to help control blood sugar in adult patients with type 2 diabetes who do not have sufficient blood sugar control through diet and exercise, particularly in overweight individuals. It can be used alone or in combination with other oral hypoglycemic agents or insulin for effective treatment tailored to each patient's condition. This helps stabilize blood sugar levels and improves diabetes symptoms.

How to take

Adult dose

The dose should be determined individually based on efficacy and tolerability, and the recommended maximum daily dose should not be exceeded. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week. A maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg 2 times daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - During treatment initiation and dose adjustment, measure fasting blood glucose to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The treatment goal with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine should be discontinued immediately.

Precautions

This medication can rarely cause serious lactic acidosis; if symptoms appear, medical personnel should be notified immediately. Caution is required when used in conjunction with other diabetes medications due to the risk of hypoglycemia. It should not be administered to patients with moderate or severe renal impairment, dehydration, or acute conditions such as severe infections. This medication should also not be used in cases of acute heart failure, myocardial infarction, or sepsis that can affect renal function. Before and after examinations using iodinated contrast agents, the administration of this medication should be discontinued for a certain period and resumed only after renal function has returned to normal. It should not be given to patients who have had allergic reactions to any components of this medication or to type 1 diabetes patients, or those with a history of lactic acidosis or ketoacidosis. In cases of severe infections, severe trauma, or around surgery, the use of this medication should be temporarily halted until the patient's condition stabilizes, at which point it can be resumed. Irregular meals or intense exercise, and interactions with other medications can increase the risk of lactic acidosis and hypoglycemia, requiring caution. Regular monitoring of renal function is advisable during the use of this medication, and any abnormalities should be addressed immediately. Vitamin B12 deficiency may occur, so it is advisable to periodically check serum vitamin B12 levels. Gastrointestinal disturbances can occur but generally improve naturally during early treatment. Alcohol consumption can increase the risk of lactic acidosis; therefore, it is important not to overindulge while taking this medication. During pregnancy, this medication may affect the fetus; therefore, if you plan to become pregnant or are pregnant, consult your doctor. If breastfeeding, consult your doctor on whether to continue breastfeeding or to stop medication as this drug may be excreted in breast milk. Elderly patients are prone to renal function decline, so dosage adjustments and frequent renal function testing are necessary. In case of overdose, hypoglycemia is rare but there is a risk of lactic acidosis, requiring immediate medical treatment. This medication should be swallowed whole without crushing or chewing the tablet, and the tablet coating may appear in the stool, which is normal. During the use of this medication, regular blood sugar, glycosylated hemoglobin, renal function, and hematological tests should be performed to monitor treatment effects and side effects.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container protected from air and moisture. It is also advisable to keep it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White rectangular extended-release film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.